| Revenue Growth | US sales up 11%; International up 3%; Foundational 8%; Therapeutic 11%. |
|---|---|
| Mgmt Confidence | High confidence in meeting three-year CGI targets; raised full-year 2026 guidance. |
| Demand Visibility | Strong pipeline for Viewpoint; better than expected demand in primary categories. |
| Margin Trends | Operating margin 21.3% up 160bps; Gross margin 52.8% down 81bps. |
| Op. Leverage | Operating expenses increased only 1% against 8% revenue growth. |
| Vol vs Price | Growth driven by strong demand across foundational and therapeutic product categories. |
| Segment Growth | OEM up 15%; Oncology up 16%; Foundational products organic growth 8%. |
| New Clients | Strong pipeline of evaluations at academic institutions for Viewpoint Medical products. |
| Capex & Debt | Acquired SoloPace for $45M; Net leverage ratio 1.5x; $505.8M cash. |
| Regulatory | Monitoring China VBP and potential Section 232 tariff impacts. |
| Commentary | Focusing on 'right to win' high-growth procedures in 2027-2029 strategic plan. |
| New Launches | Launched Scout MD in May; integrating SoloPace for TAVR procedures. |
Growth
Total revenue $416M up 8%; organic growth 9%; non-GAAP EPS increased 22% year-over-year.
Outlook
Raised 2026 organic growth to 7.1%-7.6% and non-GAAP EPS to $4.33-$4.37.
Risks
Gross margins declined 81bps due to manufacturing variances, freight, and platinum costs.
The company's earnings call, NASDAQ: MMSI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Merit Medical Systems Inc: key numbers
- Share price
- $86.35Close, Nov 16
- Market cap
- $5.17B
- Shares outstanding
- 59.92MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Merit Medical Systems Inc
All →Merit Medical Systems CLO, Secretary Brian G. Lloyd Sells $1.44M of Stock
Brian G. Lloyd, CLO, Secretary, sold 16,722 shares of Merit Medical Systems Inc at $86.33 a share, worth $1.44M in total on Nov 16, 2026. Shares held after the trade: 60,132 (-21.8%).
- Value
- $1.44M
- Shares
- 16,722
- Price
- $86.33
- Role
- CLO, Secretary
- Holding change
- -21.8%
- Trade date
- Nov 16, 2026
Merit Medical Systems Q3 2026 Results: Net Income $42.3M, Up 52.4% YoY
Merit Medical Systems reported net sales of $1.22 billion for the nine months ended September 30, 2026, representing an 8.5% increase over the prior year. Net income for the same period rose significantly to $122.1 million, up from $90.5 million in 2025, driven by improved gross margins and controlled operating expenses.
- Key figure
- Net income $42.3M · +52.4% YoY
Merit Medical Systems Financial Results
Merit Medical Systems reported Q3 2026 financial results with 8.4% revenue growth and raised its full-year 2026 guidance. The company also disclosed the $45 million cash acquisition of Solo Pace, Inc., which was completed on October 13, 2026.
- Counterparty
- Solo Pace, Inc.
“Merit delivered third quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture.”
Martha G. Aronson, Merit’s President and CEO
“We have raised our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first nine months of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year.”
Martha G. Aronson, Merit’s President and CEO